Akari Therapeutics (AKTX) Competitors $0.98 -0.07 (-6.64%) Closing price 02/21/2025 03:54 PM EasternExtended Trading$0.98 -0.01 (-0.51%) As of 02/21/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends AKTX vs. MIST, VTYX, COYA, TCRX, CRDL, JMAC, EPRX, SAVA, DERM, and VIGLShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Milestone Pharmaceuticals (MIST), Ventyx Biosciences (VTYX), Coya Therapeutics (COYA), TScan Therapeutics (TCRX), Cardiol Therapeutics (CRDL), Maxpro Capital Acquisition (JMAC), Eupraxia Pharmaceuticals (EPRX), Cassava Sciences (SAVA), Journey Medical (DERM), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Milestone Pharmaceuticals Ventyx Biosciences Coya Therapeutics TScan Therapeutics Cardiol Therapeutics Maxpro Capital Acquisition Eupraxia Pharmaceuticals Cassava Sciences Journey Medical Vigil Neuroscience Akari Therapeutics (NASDAQ:AKTX) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Do analysts rate AKTX or MIST? Milestone Pharmaceuticals has a consensus target price of $13.00, suggesting a potential upside of 537.25%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Milestone Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to AKTX or MIST? In the previous week, Akari Therapeutics had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Akari Therapeutics and 3 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.63 beat Akari Therapeutics' score of 0.13 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in AKTX or MIST? 5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by company insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, AKTX or MIST? Akari Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Does the MarketBeat Community favor AKTX or MIST? Akari Therapeutics received 180 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 69.49% of users gave Milestone Pharmaceuticals an outperform vote while only 50.68% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26250.68% Underperform Votes25549.32% Milestone PharmaceuticalsOutperform Votes8269.49% Underperform Votes3630.51% Which has higher valuation and earnings, AKTX or MIST? Akari Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/AMilestone Pharmaceuticals$1M108.79-$59.69M-$0.81-2.52 Is AKTX or MIST more profitable? Akari Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Milestone Pharmaceuticals N/A -151.82%-49.85% SummaryMilestone Pharmaceuticals beats Akari Therapeutics on 8 of the 14 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.06M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book-32.836.717.644.62Net Income-$10.01M$138.33M$3.18B$245.85M7 Day Performance-9.13%-2.63%-2.00%-2.61%1 Month Performance-21.83%-2.33%-0.44%-2.14%1 Year Performance-56.03%-5.33%16.44%12.98% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$0.99-6.6%N/A-58.6%$28.06MN/A0.009Analyst ForecastNews CoverageGap DownMISTMilestone Pharmaceuticals2.8119 of 5 stars$2.23+3.7%$13.00+483.0%+29.1%$118.93M$1M-2.7530VTYXVentyx Biosciences3.1131 of 5 stars$1.67-3.5%$10.00+498.8%-68.1%$118.09MN/A-0.7130Upcoming EarningsCOYACoya Therapeutics1.4378 of 5 stars$6.88+0.7%$16.25+136.2%-26.3%$114.97M$6M-10.586TCRXTScan Therapeutics2.4738 of 5 stars$2.14-1.8%$11.25+425.7%-68.8%$114.21M$21.05M-2.02100CRDLCardiol Therapeutics2.8854 of 5 stars$1.37+1.5%$8.40+513.1%-18.4%$113.18MN/A-3.5120News CoverageJMACMaxpro Capital AcquisitionN/A$8.35+0.6%N/A+1,067.4%$112.12MN/A0.002,021EPRXEupraxia Pharmaceuticals3.4167 of 5 stars$3.14-2.1%$9.00+186.5%N/A$111.88MN/A-4.3629Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeSAVACassava Sciences3.7798 of 5 stars$2.32+2.2%$111.50+4,706.0%-88.5%$111.62MN/A-1.6830Gap UpDERMJourney Medical2.5274 of 5 stars$5.24+5.0%$9.38+78.9%+38.0%$109.46M$79.18M-5.5790VIGLVigil Neuroscience3.1884 of 5 stars$2.65+0.4%$19.75+645.3%+0.3%$108.33MN/A-1.2940 Related Companies and Tools Related Companies Milestone Pharmaceuticals Competitors Ventyx Biosciences Competitors Coya Therapeutics Competitors TScan Therapeutics Competitors Cardiol Therapeutics Competitors Maxpro Capital Acquisition Competitors Eupraxia Pharmaceuticals Competitors Cassava Sciences Competitors Journey Medical Competitors Vigil Neuroscience Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts